Elsevier

Placenta

Volume 18, Issues 2–3, March–April 1997, Pages 205-210
Placenta

Original article
Human placental norepinephrine transporter mRNA: Expression and correlation with fetal condition at birth

https://doi.org/10.1016/S0143-4004(97)90094-1Get rights and content

Abstract

The purpose of this study was to determine the primary form of human placental norepinephrine transporter (hNET) mRNA expressed in the human placenta and to compare the level of expression in normal pregnancies and in pregnancies complicated by drug exposure or other forms of physiological derangement. We used the hNET cDNA to measure RNA extracted from placenta and examined placental RNA following complicated and uncomplicated pregnancies. To compare transporter expression and its relation to fetal condition at birth, umbilical arterial plasma catecholamine levels, umbilical arterial blood gases and placental transporter mRNA level were compared by linear regression analysis. Uncomplicated pregnancies had a higher level of placental norepinephrine transporter mRNA than complicated pregnancies. An inverse relationship between umbilical cord norepinephrine level and transporter expression was demonstrated. We conclude that placental transporter expression represents an important and newly described metabolic function of the placenta. Placental catecholamine clearance mediated via the placental NET may be important in the pathophysiology of disorders associated with placental dysfunction, impaired placental blood flow or intrauterine growth retardation. This may also explain the adverse effects of drugs, such as cocaine, which block catecholamine transport.

References (33)

  • Y.T. Tseng et al.

    Transcriptional regulation of β1-adrenergic receptors by corticosteroids and thyroid hormone in fetal sheep

    European Journal of Pharmacology: Molecular Pharmacology

    (1995)
  • W. Al-Ghazalin et al.

    Evidence of redistribution of cardiac output in asymmetrical growth retardation

    British Journal of Obstetrics and Gynaecology

    (1989)
  • L. Bzoskie et al.

    Placental norepinephrine Clearance: in vivo measurement and physiological role

    American Journal of Physiology

    (1995)
  • W.A. Case et al.

    Differences in dopamine clearance and diffusion in rat striatum and nucleus accumbens following systemic cocaine administration

    Journal of Neurochemistry

    (1992)
  • B.A. Chappell et al.

    Pulmonary clearance of norepinephrine in lambs

    Paediatric Research

    (1991)
  • D. Davidson

    Circulating vasoactive substances and hemodynamic adjustments at birth in lambs

    Journal of Applied Physiology

    (1987)
  • Cited by (34)

    • Transfer of maternal psychosocial stress to the fetus

      2020, Neuroscience and Biobehavioral Reviews
    • Acute psychiatric illness and drug addiction during pregnancy and the puerperium

      2020, Handbook of Clinical Neurology
      Citation Excerpt :

      Blocking of norepinephrine and serotonin transporters may increase the concentration of norepinephrine and serotonin 5-hydroxytryptamine (5HT), resulting in narrowing of blood vessels and decrease in blood flow to the placenta (Ramamoorthy et al., 1995). Also, the downregulation of the placental norepinephrine transporter due to amphetamine can result in an increase in circulating catecholamines, downregulation of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD-2), and chronic fetal hypercortisolism, which can cause behavioral problems such as excitement and attention deficit by changing the HPA axis (Bzoskie et al., 1997). The effects of using amphetamine during pregnancy include a higher risk of preeclampsia, preterm birth, more cesarean sections, RCVS, and more maternal morbidity and mortality (Ducros, 2012; Oei et al., 2012).

    • Passive Addiction and Teratogenic Effects

      2018, Volpe's Neurology of the Newborn
    • Role of catecholamines in maternal-fetal stress transfer in sheep

      2015, American Journal of Obstetrics and Gynecology
      Citation Excerpt :

      Fetal catecholamine homeostasis is maintained through the placental reuptake of neurotransmitters contributing to nearly 50% of the total fetal NE clearance.37 Catecholamine reuptake is achieved by the placental NE transporter,38 which expression is known to be impaired with placental dysfunction or fetal distress.39 Thus, fetal plasma catecholamine concentration is low under physiological conditions though fetal catecholamine production is high compared to postnatal conditions.40

    • Reconceptualizing in a dual-system model the effects of prenatal cocaine exposure on adolescent development: A short review

      2011, International Journal of Developmental Neuroscience
      Citation Excerpt :

      Serving as a barrier to high levels of maternal glucocorticoids, the key enzyme to protect fetal HPA-axis development is placental 11β-HSD-2 (White et al., 1997). Sarkar and colleagues investigated the regulatory mechanism of the 11β-HSD-2 enzyme and found that 11β-HSD-2 gene expression was downregulated by catecholamines, which in turn was affected by maternal cocaine use since the main molecular targets of cocaine binding were catecholamine transporters (Bzoskie et al., 1997; Sarkar et al., 2001). Maternal cocaine use may have deleterious effects on the development of the fetal HPA-axis by weakening protections from the 11β-HSD-2 gene (Lester and Padbury, 2009).

    • Fetal Effects of Psychoactive Drugs

      2009, Clinics in Perinatology
      Citation Excerpt :

      Blockage of these transporters increases the concentrations of norepinephrine and serotonin, resulting in constriction of blood vessels and decreased blood flow to the placenta. Also, placental NET downregulation resulting from MA could lead to increases in circulating catecholamines, downregulation of 11β-HSD-2, and chronic fetal hypercortisolism,28,59 which could affect behavior through alteration of the hypothalamic-pituitary-adrenal axis, especially arousal regulation and attention.43 Each year at least 600,000 infants born in the United States are exposed to maternal major depressive disorder during gestation, which is associated with newborn medical and neurobehavioral deficits and long-term emotional, behavioral, and social problems in the child.

    View all citing articles on Scopus
    View full text